{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.92","upperLimit":"5.59","value":"1.68"},{"comment":"The upper limit of the CI is below the level of detection.","groupId":"OG001","lowerLimit":"3.55","upperLimit":"NA","value":"5.78"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"description":"The progression-free survival is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who started on placebo and crossed over to active drug.\n\nAdults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off\n\nRegorafenib\n\nRegorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off","id":"OG000","title":"Cohort A: Liposarcoma Crossover"},{"description":"Participants who started on placebo and crossed over to active drug.\n\nAdults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off\n\nRegorafenib\n\nRegorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off","id":"OG001","title":"Cohort B: Osteosarcoma Crossover"}],"paramType":"MEDIAN","populationDescription":"Participants who started on placebo in Cohorts A and B, then crossed over to active drug after progression.","reportingStatus":"POSTED","timeFrame":"up to 3 years","title":"Progression-free Survival (PFS), Cohorts A and B, After Crossover.","type":"SECONDARY","unitOfMeasure":"months"}